At a glance
- Originator Cephalon
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 26 Mar 2007 Discontinued - Preclinical for Pain in USA (PO)
- 04 Mar 2003 No development reported - Preclinical for Pain in USA (unspecified route)
- 05 Dec 2000 Preclinical development for Pain in USA (Unknown route)